Compound
Everything we've written on AMPK — 8 articles covering the mechanism, the evidence, comparisons, and practical considerations.
8 articles
Metabolic healthWhat people are reporting about AICAR — the "exercise in a pill"This article summarizes experiences reported in public online communities including Reddit, longevity forums, and discussion boards. We are not advocating human use of any compound discussed here. Many of the peptides discussed are not FDA-approved for the uses described, and some are explicitly not approved for human or veterinary use. What follows is a synthesis of what people have reported, presented to give readers context on the public conversation — not as guidance, not as evidence of safety or efficacy, and not as a recommendation. Decisions about any compound should be made with a qualified prescribing provider after a full medical evaluation.8 min readMetabolic healthAICAR — the AMPK agonist and the "exercise mimetic" conversationIn 2008, a paper came out of the Salk Institute that generated the kind of headlines science usually doesn't get to produce. Sedentary mice that had received a compound called AICAR for four weeks ran 44 percent longer on a treadmill than untreated mice, despite having done no prior training. The researcher behind it, Ronald Evans — a Howard Hughes Investigator who had spent years studying the genetics of exercise adaptation — described it as a potential exercise pill. The phrase landed. It bounced across science publications and general media, and it planted an idea that persists: that the metabolic benefits of exercise might be chemically replicable, that the adaptation could be achieved without the effort.8 min readMitochondrial healthAMPK — the cellular energy sensor and why metformin became a longevity drugMetformin has been prescribed to people with type 2 diabetes since the 1950s in Europe and since 1995 in the United States. It is among the most prescribed drugs in the world, with a safety profile that decades of clinical use have established as genuinely good. For most of that time, nobody fully understood how it worked. The pharmacological mechanism — what it was actually doing in the cell to lower blood glucose — was the subject of debate for more than forty years. The explanation, when it arrived in the early 2000s, turned out to be more interesting than a diabetes mechanism. It pointed at a kinase that sits at the center of cellular energy sensing, and through that kinase it connected metformin to a biology that reaches from mitochondria to mTOR to lifespan.11 min readMitochondrial healthMitochondrial biogenesis — how cells build more power plants, and why it fades with ageMitochondria were not always part of us. The leading account of their origin, championed and made rigorous by the biologist Lynn Margulis in the late 1960s against considerable resistance, is that more than a billion years ago a free-living bacterium was engulfed by a larger cell and, instead of being digested, struck a bargain. The bacterium supplied energy; the host supplied shelter and raw materials. Over deep time the guest became a permanent resident, surrendering most of its genome to the host nucleus but keeping a small loop of its own DNA — which mitochondria carry to this day. This endosymbiotic event is arguably the most consequential merger in the history of life, because the energy it unlocked made complex, large-celled organisms possible. Every breath you take feeds these descendants of an ancient bacterium, and the question of how a cell decides to build more of them sits at the center of modern metabolic and longevity science.8 min readMetabolic healthMOTS-c for athletic performance and the exercise mimetic questionYou're thirty-eight, or forty-two, and the training hasn't changed that much. You're still putting in the hours. You're still doing the things that worked. But the baseline has shifted — the recovery takes longer than it used to, the metabolic flexibility that let you run hard and bounce back has grown sluggish, and the same effort that used to leave you feeling sharp now leaves you grinding through the back half of the week. Your body has changed the math on you without telling you what changed.8 min readMetabolic healthMOTS-c and insulin sensitivity — what animal research has exploredThe weight that arrives in your forties doesn't announce itself as a metabolic problem. It shows up as pants that fit differently, a number on the scale that moves stubbornly in one direction despite the same habits that kept it stable for years, an afternoon energy dip that coffee doesn't fix the way it used to. You eat more carefully and exercise more deliberately and the situation improves slowly if at all, or it cycles — better for a stretch, then quietly worse. Nobody says "insulin resistance" until something dramatic happens. Before that, the story is just: your body isn't responding to what worked before.6 min readMitochondrial healthMOTS-c in plain English — mitochondrial-derived peptides explainedYour mitochondria are not quiet. They're not just burning fuel and staying out of the way. They're running a continuous metabolic read on the cell's energy state and broadcasting updates — and those updates, it turns out, include peptides that circulate through the body and communicate with tissues that have nothing to do with where the mitochondria physically sit. MOTS-c is one of those peptides. Understanding what it actually does requires starting with what the cell does when energy runs low.8 min readAnti-aging and cellular healthNutrient sensing — the four pathways that decide between growth and longevityIn the early 1990s, on the remote Pacific island of Rapa Nui — Easter Island — researchers studying a soil bacterium called Streptomyces hygroscopicus isolated a compound the bacterium used to suppress competing fungi. They named it after the island: rapamycin. For years it was developed as an antifungal, then as an immunosuppressant to prevent organ-transplant rejection. Only later, when biologists traced exactly how it worked, did they find that rapamycin acts on a single protein so central to how cells decide whether to grow that they named the protein after the drug: the mechanistic target of rapamycin, mTOR. That a fungus-fighting molecule from an island soil bacterium turned out to be a key that fits one of the master switches of cellular aging is one of the stranger origin stories in biology — and it opens directly onto the question of how cells know whether it is time to grow or time to endure.7 min read